Deborah Toppmeyer

PROF-TE-DIV CHIEF, Cancer Institute of New Jersey (CINJ), Breast Oncology
ASSOCIATE MEMBER, Clinical Investigations and Precision Therapeutics Program, CINJ

Emailtoppmede@rutgers.edu

3061 Citations
22 h-Index

If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Deborah Toppmeyer is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

15 Similar Profiles

Breast Neoplasms Medicine & Life Sciences

Neoplasms Medicine & Life Sciences

Paclitaxel Medicine & Life Sciences

Recurrence Medicine & Life Sciences

Drug Therapy Medicine & Life Sciences

9-aminocamptothecin Medicine & Life Sciences

Triple Negative Breast Neoplasms Medicine & Life Sciences

Mutation Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1992 2019

3061 Citations
22 h-Index
45 Article
8 Review article
1 Editorial
1 Letter

5-Year Results of a Prospective Phase 2 Trial Evaluating 3-Week Hypofractionated Whole Breast Radiation Therapy Inclusive of a Sequential Boost

Gupta, A., Khan, A., Yegya-Raman, N., Sayan, M., Ahlawat, S., Ohri, N., Goyal, S., Moore, D., Eladoumikdachi, F., Toppmeyer, D. & Haffty, B., Oct 1 2019, In : International Journal of Radiation Oncology Biology Physics. 105, 2, p. 267-274 8 p.

Research output: Contribution to journal › Article

acceleration (physics)

breast

radiation therapy

Breast

Radiotherapy

3 Citations (Scopus)

A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance)

Rashkin, S. R., Chua, K. C., Ho, C., Mulkey, F., Jiang, C., Mushiroda, T., Kubo, M., Friedman, P. N., Rugo, H. S., McLeod, H. L., Ratain, M. J., Castillos, F., Naughton, M., Overmoyer, B., Toppmeyer, D., Witte, J. S., Owzar, K. & Kroetz, D. L., Mar 1 2019, In : Clinical pharmacology and therapeutics. 105, 3, p. 738-745 8 p.

Research output: Contribution to journal › Article

Pharmacogenetics

Disease-Free Survival

Area Under Curve

Genome

Breast Neoplasms

Decisional conflict among breast cancer patients considering contralateral prophylactic mastectomy

Manne, S., Smith, B., Mitarotondo, A., Frederick, S., Toppmeyer, D. & Kirstein, L., May 1 2019, In : Patient Education and Counseling. 102, 5, p. 902-908 7 p.

Research output: Contribution to journal › Article

Breast Neoplasms

Self Efficacy

Motivation

Neoplasms

Foster Home Care

24 Citations (Scopus)

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: Cohort A of the phase II KEYNOTE-086 study

Adams, S., Schmid, P., Rugo, H. S., Winer, E. P., Loirat, D., Awada, A., Cescon, D. W., Iwata, H., Campone, M., Nanda, R., Hui, R., Curigliano, G., Toppmeyer, D., O'Shaughnessy, J., Loi, S., Paluch-Shimon, S., Tan, A. R., Card, D., Zhao, J., Karantza, V. & 1 others, Cortés, J., Mar 1 2019, In : Annals of Oncology. 30, 3, p. 397-404 8 p.

Research output: Contribution to journal › Article

Triple Negative Breast Neoplasms

Therapeutics

Population

Safety

pembrolizumab

17 Citations (Scopus)

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: Cohort B of the phase II KEYNOTE-086 study

Adams, S., Loi, S., Toppmeyer, D., Cescon, D. W., De Laurentiis, M., Nanda, R., Winer, E. P., Mukai, H., Tamura, K., Armstrong, A., Liu, M. C., Iwata, H., Ryvo, L., Wimberger, P., Rugo, H. S., Tan, A. R., Jia, L., Ding, Y., Karantza, V. & Schmid, P., Mar 1 2019, In : Annals of Oncology. 30, 3, p. 405-411 7 p.

Research output: Contribution to journal › Article

Triple Negative Breast Neoplasms

Therapeutics

Disease-Free Survival

pembrolizumab

Safety